What question did this study set out to answer?

This research examines the role of surrogate endpoints in evaluating health outcomes during the drug approval process for cardiovascular disease treatment.

August 25, 1999JAMA

Surrogate End Points, Health Outcomes, and the Drug-Approval Process for the Treatment of Risk Factors for Cardiovascular Disease

View Full Paper

Ask AI

Bookmark

Authors

BPBruce M. PsatyUniversity of Washington

Discussion

Member takes

Implication

This article explores surrogate endpoints affecting health outcomes in drug approval processes for cardiovascular risk factors, indicating significant implications for treatment effectiveness.

Key Points

This research examines the role of surrogate endpoints in evaluating health outcomes during the drug approval process for cardiovascular disease treatment.
Analysis of existing literature on surrogate endpoints and drug approval guidelines.
Evaluation of health outcomes associated with various cardiovascular risk factor treatments.
Identification of key surrogate endpoints that correlate with positive health outcomes.
Analysis highlights inconsistencies in how surrogate endpoints are used in approval processes.

Cite This Study

Bruce M. Psaty (1999) studied this question.

synapsesocial.com/papers/6a24307eb0bade69f19ff73e https://doi.org/10.1001/jama.282.8.786

View Full Paper

Ask AI

Bookmark

Implication

This article explores surrogate endpoints affecting health outcomes in drug approval processes for cardiovascular risk factors, indicating significant implications for treatment effectiveness.

Surrogate End Points, Health Outcomes, and the Drug-Approval Process for the Treatment of Risk Factors for Cardiovascular Disease

Discussion

Member takes

Implication

Key Points

Cite This Study

Surrogate End Points, Health Outcomes, and the Drug-Approval Process for the Treatment of Risk Factors for Cardiovascular Disease

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider